Haemolytic-uremic syndrome associated with infection

Czech version

Authors: J. Sagan ^1,2; M. Bielaszewska ³; M. Havlíčková ³
Authors‘ workplace: Klinika infekčního lékařství FN Ostrava ¹; Katedra interních oborů, LF OU, Ostrava ²; Státní zdravotní ústav, Centrum epidemiologie a mikrobio logie, Národní referenční laboratoř pro E. coli a shigely ³
Published in: Transfuze Hematol. dnes,30, 2024, No. S1, p. 30-35.
Category:
doi: https://doi.org/10.48095/cctahd2024suppl1S30

Overview

Haemolytic-uraemic syndrome (HUS) is a form of thrombotic microangiopathy. It is characterised by acute kidney injury, non-immune Coombs-negative haemolytic anaemia, and thrombocytopenia. Typical HUS is a serious disease that develops as a consequence of diarrhoea caused by Shiga toxin-producing Escherichia coli (STEC) strains, which can be detected in a patient’s stool culture. The disease primarily affects preschool children. The infection occurs mostly through ingestion of STEC-contaminated food. The clinical course is dominated by abdominal pain often accompanied by cramps and diarrhoea with or without blood, icterus, and acute kidney injury with haematuria, proteinuria, and elevated kidney function parameters. At the same time, skin and mucosal bleeding of various extent occurs. central nervous system involvement may develop as a life-threatening complication. It is important to timely recognize and treat patients in an intensive care unit with the possibility of haemodialysis.

Keywords:

Escherichia coli – thrombotic microangiopathy – acute kidney injury – children – haemolytic-uraemic syndrome – Shiga toxin

Sources

1. Gasser C, Gautier E, Steck A, et al. Hämolytisch urämische Syndrom: Bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr. 1955; 85: 905–909.

2. Gillespie RS, Wong CS, Prauner RD. Pediatric hemolytic uremic syndrom. Available from: https: //emedicine.medscape.com/article/ 982025-overview#a6.

3. Zieg J, Bláhová K, Dušek J, et. al. Hemolyticko-uremický syndrom. Ped Prax. 2011; 12 (2): 102–104.

4. Bláhová K, Malina M, Šuláková T. Trombotické mikroangiopatie – hemolyticko-uremický syndrom a trombotická trombocytopenická purpura. In: Seeman T, Janda J. Dětská nefrologie. Praha: Mladá fronta 2015; str. 311–317.

5. Karmali MA, Steele BT, Petric M, et al. Sporadic cases of haemolytic uremic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983; i: 619–620.

6. Konowalchuk J, Speirs JI, Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun. 1977; 18: 775–779.

7. Karpman D, Loos S, Tati R, et al. Haemolytic uraemic syndrome. J Intern Med. 2016; 281: 123–148.

8. Karnišová L, Fencl F, Marejková M, et. al. Infekce způsobené Shiga toxin-produkujícími Escherichia coli u dětí. Cesko-Slov Ped. 2016; 71 (2): 98–103.

9. Riley LW, Remis RS, Helgerson SD, et. al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983; 308: 681–685.

10. Friedman MS, Roels T, Koehler JE, et al. Escherichia coli O157: H7 outbreak associated with an improperly chlorinated swimming pool. Clin Infect Dis. 1999; 29: 298–303.

11. Loos S, Ahlenstiel T, Kranz B, et al. An outbreak of Shiga toxin-producing Escherichia coli O104: H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis. 2012; 55 (6): 753–759.

12. Kielstein J, Beutel G, Brunkhorst R, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104: H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dialysis Transplant. 2012; 27 (10): 3807–3815.

13. Marejková M, Zieg J, Dušek J, et al. Smrtelný případ diareapozitivního hemolyticko-uremického syndromu vyvolaného enterohemoragickým Escherichia coli O26. Zprávy CEM (SZÚ Praha). 2009; 18 (6): 212–214.

14. Marejková M, Bláhová K, Janda J, et al. Enterohemorrhagic Escherichia coli as causes of hemolytic uremic syndrome in the Czech Republic. PLoS One. 2013; 8 (9): e73927.

15. Smith DG, Naylor SW, Gally DL. Consequences of EHEC colonisation in humans and cattle. Int J Med Microbiol. 2002; 292: 169–218.

16. Ludwig K, Sarkim V, Bitzan M, et al. Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol. 2002; 40 (5): 1773–1782.

17. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin–producing Escherichia coli O104: H4 outbreak in Germany. N Engl J Med. 2011; 365 (19): 1771–1780.

18. Bielaszewska M, Mellmann A, Zhang W, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis. 2011; 11 (9): 671–676.

19. Mellmann A, Harmsen D, Cummings CA, et al. Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104: H4 outbreak by rapid next generation sequencing technology. PLoS One. 2011; 6 (7): e22751.

20. Buchholz U, Bernard H, Werber D, et al. German outbreak of Escherichia coli O104: H4 associated with sprouts. N Engl J Med. 2011; 365 (19): 1763–1770.

21. Tarr PI, Gordon CA, Chandler WL. Shiga toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005; 365 (9464): 1073–1086.

22. Durkan A, Menascu S, Langlois V. Isolated abducens nerve palsy in hemolytic uremic syndrome. Pediatr Nephrol. 2004; 19 (8): 915–916.

23. Thayu M, Chandler WL, Jelacic S, et al. Cardiac ischemia during hemolytic uremic syndrome. Pediatr Nephrol. 2003; 18: 286–289.

24. Robitaille P, Gonthier M, Grignon A, et al. Pancreatic injury in the hemolytic-uremic syndrome. Pediatr Nephrol. 1997; 11: 631–632.

25. Melton-Celsa AR. Shiga toxin (Stx) classification, structure, and function. Microbiol Spectr. 2014; 2 (4): EHEC-0024-2013.

26. Bielaszewska M, Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost. 2005; 94 (2): 312–318.

27. Betz J, Dorn I, Kouzel IU, et al. Shiga toxin of enterohaemorrhagic Escherichia coli directly injures developing human erythrocytes. Cell Microbiol. 2016; 18 (10): 1339–1348.

28. Ryšavá R. Atypický hemolyticko-uremický syndrom a nové možnosti léčby. Int Med Prax. 2014; 16 (1): 22–25.

29. Obrig TG. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins. 2010; 2 (12): 2769–2794.

30. Orth D, Würzner R. Complement in typical hemolytic uremic syndrome. Semin Thromb Hemost. 2010; 36 (6): 620–624.

31. Calderon Toledo C, Arvidsson I, Karpman D. Cross-reactive protection against enterohemorrhagic Escherichia coli infection by enteropathogenic E. coli in a mouse model. Infect Immun. 2011; 79: 2224–2233.

32. Remuzzi G, Ruggenenti P. The hemolytic-uremic syndrome. Kidney Int. 1995; 48: 2–19.

33. Karpman D, Hakansson A, Perez MT, et al. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infect Immun. 1998; 66: 636–644.

34. McGraw ME, Lendon M, Stevens RF, et al. Haemolytic uraemic syndrome and the Thomsen Friedenreich antigen. Pediatr Nephrol. 1989; 3 (2): 135–139.

35. Watanabe T. Renal complications of seasonal and pandemic influenza A virus infections. Eur J Pediatr. 2013; 172 (1): 15–22.

36. Tarr PI, Neill MA, Clausen CR, et al. Escherichia coli O157: H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J Infect Dis. 1990; 162 (2): 553–556.

37. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. 2005; 295: 405–418.

38. Walsh PR, Johnson S. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol. 2019; 34 (9): 1485–1492. doi: 10.1007/s00467-018-4025-0.

39. Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic-uremic syndrome: An update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019; 23 (1): 4–21. doi: 10.1111/1744-9987.12763.

40. Caletti MG, Lejarraga H, Kelmansky D, Missoni M. Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome. Pediatr Nephrol. 2004; 19: 1148–1152

41. Wong CS, Mooney JC, Brandt JR, et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157: H7: a multivariable analysis. Clin Infect Dis. 2012; 55: 33–41.

42. Tajiri H, Nishi J, Ushijima K, et al. A role for fosfomycin treatment in children for prevention of haemolytic-uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection. Int J Antimicrob Agents. 2015; 46 (5): 586–589.

43. Zieg J. Hemolyticko-uremický syndrom u dětí. Pediatr Prax. 2020; 21 (5): 311–314.

44. Wildes DM, Harvey S, Costigan CS, et al. Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement. Pediatr Nephrol. 2024; 39 (1): 315–324. doi: 10.1007/s00467- 023-06102

PODÍL AUTORŮ NA RUKOPISU

JS – napsání rukopisu

MB, MH – revize rukopisu

PROHLÁŠENÍ AUTORŮ

Autoři práce prohlašují, že v souvislosti s tématem, vznikem a publikací tohoto článku nejsou ve střetu zájmů a vznik ani publikace článku nebyly podpořeny žádnou farmaceutickou firmou.

Do redakce doručeno dne: 4. 12. 2023.

Přijato po recenzi dne: 8. 7. 2024.

MUDr. Jiří Sagan

Klinika infekčního lékařství

FN Ostrava

e-mail: jiri.sagan@fno.cz